Summary
Global Markets Direct’s, ‘Zealand Pharma A/S - Product Pipeline Review - 2016’, provides an overview of the Zealand Pharma A/S’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Zealand Pharma A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Zealand Pharma A/S
- The report provides overview of Zealand Pharma A/S including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Zealand Pharma A/S’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Zealand Pharma A/S’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Zealand Pharma A/S’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Zealand Pharma A/S
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Zealand Pharma A/S’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Zealand Pharma A/S Snapshot 5
Zealand Pharma A/S Overview 5
Key Information 5
Key Facts 5
Zealand Pharma A/S - Research and Development Overview 6
Key Therapeutic Areas 6
Zealand Pharma A/S - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Zealand Pharma A/S - Pipeline Products Glance 14
Zealand Pharma A/S - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Zealand Pharma A/S - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Zealand Pharma A/S - Drug Profiles 17
ZP-1848 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
ZP-4207 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
ZP-2929 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Synthetic Peptide for Diabetes and Obesity 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Synthetic Peptides for Undisclosed Indications 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
ZP-3022 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
ZPDI-70 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
ZPGG-23 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
ZPGG-72 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ZPI-98 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Zealand Pharma A/S - Pipeline Analysis 27
Zealand Pharma A/S - Pipeline Products by Target 27
Zealand Pharma A/S - Pipeline Products by Route of Administration 28
Zealand Pharma A/S - Pipeline Products by Molecule Type 29
Zealand Pharma A/S - Pipeline Products by Mechanism of Action 30
Zealand Pharma A/S - Recent Pipeline Updates 31
Zealand Pharma A/S - Dormant Projects 34
Zealand Pharma A/S - Locations And Subsidiaries 35
Head Office 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 36
Disclaimer 37
List of Tables
Zealand Pharma A/S, Key Information 5
Zealand Pharma A/S, Key Facts 5
Zealand Pharma A/S - Pipeline by Indication, 2016 7
Zealand Pharma A/S - Pipeline by Stage of Development, 2016 8
Zealand Pharma A/S - Monotherapy Products in Pipeline, 2016 9
Zealand Pharma A/S - Partnered Products in Pipeline, 2016 10
Zealand Pharma A/S - Partnered Products/ Combination Treatment Modalities, 2016 11
Zealand Pharma A/S - Out-Licensed Products in Pipeline, 2016 12
Zealand Pharma A/S - Out-Licensed Products/ Combination Treatment Modalities, 2016 13
Zealand Pharma A/S - Phase II, 2016 14
Zealand Pharma A/S - Phase I, 2016 15
Zealand Pharma A/S - Preclinical, 2016 16
Zealand Pharma A/S - Pipeline by Target, 2016 27
Zealand Pharma A/S - Pipeline by Route of Administration, 2016 28
Zealand Pharma A/S - Pipeline by Molecule Type, 2016 29
Zealand Pharma A/S - Pipeline Products by Mechanism of Action, 2016 30
Zealand Pharma A/S - Recent Pipeline Updates, 2016 31
Zealand Pharma A/S - Dormant Developmental Projects,2016 34
List of Figures
Zealand Pharma A/S - Pipeline by Indication, 2016 7
Zealand Pharma A/S - Pipeline by Stage of Development, 2016 8
Zealand Pharma A/S - Monotherapy Products in Pipeline, 2016 9
Zealand Pharma A/S - Partnered Products in Pipeline, 2016 10
Zealand Pharma A/S - Out-Licensed Products in Pipeline, 2016 12
Zealand Pharma A/S - Pipeline by Target, 2016 27
Zealand Pharma A/S - Pipeline by Route of Administration, 2016 28
Zealand Pharma A/S - Pipeline by Molecule Type, 2016 29
Zealand Pharma A/S - Pipeline Products by Mechanism of Action, 2016 30
